Phytopharm neurology news

Phytopharm's board began a review of strategic options for the company, including merger and acquisition options. The review follows a full analysis of a Phase II trial to treat early Parkinson's disease (PD) showing that Cogane missed the primary endpoint. The company also said it will stop R&D expenditure and reduce headcount, but declined to disclose details (see BioCentury, Feb. 25). ...